Oracle Investment Management’s SpringWorks Therapeutics SWTX Stock Holding History

Oracle Investment Management’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-150,000	Closed	-$7.05M	–	21
2025 Q2	$7.05M	Buy	+150,000	New	+$6.67M	4.83%	4
2025 Q1	–	Sell	-55,800	Closed	-$2.02M	–	23
2024 Q4	$2.02M	Buy	+55,800	New	+$1.95M	1.1%	15
2024 Q3	–	Sell	-17,800	Closed	-$671K	–	25
2024 Q2	$671K	Sell	17,800 -25,100	-59%	-$1.06M	0.63%	17
2024 Q1	$2.11M	Sell	42,900 -207,100	-83%	-$9.57M	1.4%	13
2023 Q4	$9.13M	Buy	+250,000	New	+$6.52M	5.55%	8

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Oracle Investment Management's SWTX Position: Q2 2025 in Review

Oracle Investment Management sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 531,351 shares — an estimated $23.6M sold.

Oracle Investment Management first reported a position in SWTX in Q1 2023 and held it in 7 quarters. The position peaked at $23.4M in Q1 2025. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

Oracle Investment Management reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
Oracle Investment Management sold 531,351 SpringWorks Therapeutics shares in Q2 2025, an estimated $23.6M.
Oracle Investment Management first reported a position in SpringWorks Therapeutics in Q1 2023 and held it in 7 quarters.
Oracle Investment Management's SpringWorks Therapeutics position peaked at $23.4M in Q1 2025.
222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Oracle Investment Management's 13F filing for Q2 2025, filed 15 Aug 2025.